|
Imaging Biometrics Ltd on Friday said it has entered a research and commercial partnership with personalised cancer medicine firm Vivan Therapeutics to explore potential anti-cancer uses of gallium maltolate. Shares in Imaging Biometrics jumped 87% to 1.17 pence in London on Friday afternoon. The stock remains down 2.8% over the past year. The London-based medical services company said, under the terms of the deal, it would supply gallium maltolate, alongside partner Gallixa LLC, for evaluation using Vivan’s in vivo avatar cancer models. Vivan’s models mirror a broad spectrum of tumour molecular profiles and are tested through the company’s high-throughput platform, enabling scalable and quick assessment of investigational compounds. Gallium maltolate is a compound that has ‘already shown promise’ in glioblastoma, Imaging Biometrics said. The initial focus will be on colorectal cancer, while also extending to other conditions including pancreatic, lung, and additional gastrointestinal cancers. ‘The goal is to identify its therapeutic activity either as a single agent or in combination with existing drugs, potentially expanding its clinical utility,’ said the company. This follows the completion of Imaging Biometric’s phase 1 trial in oral gallium maltolate for adult glioblastoma, with the firm now evaluating next steps for clinical development. The collaboration with Vivan also establishes a framework for future joint development efforts, particularly around combination therapies. If opportunities are identified, both companies have agreed to pursue further co-development talks. ‘This partnership with Vivan Therapeutics marks an exciting new chapter in the exploration of gallium maltolate’s therapeutic potential,’ said Imaging Biometrics Chief Executive Officer Michael Schmainda. ‘Their unique fruit fly screening platform enables rapid, personalized testing that could accelerate the path to more effective cancer treatments involving GaM.’ Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
